Physician profile

Taylor Penick

Family · Austin, TX

NPI 1447913835

$545.20

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$184.80

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Mayne Pharma Commercial LLC $176.53 2022-2023
Hologic Sales and Service, LLC $73.19 2023 Acessa Provu System
Organon LLC $68.60 2022
Exeltis, USA INC. $67.70 2022-2024 Slynd
Dexcom, INC. $39.12 2023 Dexcom G6 Transmitter
Evofem Biosciences, INC. $34.40 2022
Alexion Pharmaceuticals, INC. $30.42 2023 Ultomiris
Shield Therapeutics INC $21.73 2022
Kaleo, INC. $19.35 2022
Avanos Medical $14.16 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Taylor Penick

$545.20

in general payments reported 2019-2025

Years
2022-2024
Top company
Mayne Pharma Commercial LLC

https://glasscript.com/doctor/11276731/taylor-penick

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.